Taysha Gene Therapies (TSHA) Research & Development (2020 - 2026)

Taysha Gene Therapies has disclosed Research & Development across 7 years of filings, most recently posting $33.8 million for Q1 2026.

• Research & Development for Q1 2026 came in at $33.8 million, up 117.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (up 619.16% YoY), and the FY2025 annual result was $3.0 million, up 200.0% from the prior year.
• Research & Development came in at $33.8 million for Q1 2026 at Taysha Gene Therapies, up from -$58.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $33.8 million in Q1 2026 to a low of -$58.5 million in Q4 2025.
• The 5-year median for Research & Development is $15.1 million (2024), against an average of $5.6 million.
• Peak annual rise in Research & Development reached 1151.4% in 2023, while the deepest fall reached 419.48% in 2023.
• Taysha Gene Therapies' Research & Development stood at $12.7 million in 2022, then sank by 419.48% to -$40.6 million in 2023, then declined by 22.37% to -$49.7 million in 2024, then declined by 17.66% to -$58.5 million in 2025, then jumped by 157.84% to $33.8 million in 2026.
• The last three Research & Development figures came in at $33.8 million (Q1 2026), -$58.5 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.